Molecular Therapeutics Research Program

Mission

The underlying mission of the Molecular Therapeutics (MT) Program is to translate laboratory findings to the clinic so as to improve the lives of patients with cancer by identifying new molecules, targets and strategies for treating cancer. This highly interactive program includes a cross section of laboratory-based scientists and physicians at Karmanos who meet regularly through programmatic activities, and serve as co-investigators on research grants and investigator-initiated clinical trials.

The MT Program’s overriding goal is to integrate basic and translational scientists working broadly in areas of drug development, new or established therapeutic targets or pathways, and cellular and genetic biomarkers of cancer, with physicians conducting interventional treatment trials at the Karmanos Cancer Institute.  

Scientific Themes

  1. Identify and validate novel therapeutics, targets and pathways for selective tumor targeting.  
  2. Identify cellular/molecular determinants and biomarkers of tumor response.  
  3. Validate clinical effectiveness of new agents in interventional treatment trials.

Program Activities

The MT Program leadership actively supports:

  • Basic-clinical collaborations and translational research through the monthly program meetings
  • Molecular Therapeutics Special Seminars
  • Focused retreats
  • Small working groups or topical conferences
  • An annual Molecular Therapeutics Program Retreat
  • Targeted internal grants with emphasis on collaboration and translational science

Program Leaders

  • Asfar S. Azmi, Ph.D.

    Molecular Therapeutics Program Leader
    Associate Professor, Oncology
    Director, Pancreas Cancer Research Initiative
    Barbara Ann Karmanos Cancer Institute
    Wayne State University School of Medicine
    azmia@karmanos.org

  • Ammar Sukari, M.D.

    Molecular Therapeutics Program Co-Leader
    Barbara Ann Karmanos Cancer Institute
    Associate Professor, Department of Oncology
    Wayne State University School of Medicine
    sukaria@karmanos.org

  • Jeffrey Zonder, M.D.

    Molecular Therapeutics Program Co-Leader
    Barbara Ann Karmanos Cancer Institute
    Professor, Departments of Hematology & Oncology
    Wayne State University School of Medicine
    zonderj@karmanos.org

The Latest From Karmanos Cancer Institute

News

U CAN-CER VIVE Gives $450K+ to Karmanos Cancer Institute for Continued Research in Using Radiofrequency to Treat Cancer

The Barbara Ann Karmanos Cancer Institute has been awarded $459,010 for continued research in treating cancers with radiofrequency electromagnetic...

Read More

New Grant Allows Karmanos Researchers to Continue Research Using Electromagnetic Radiofrequency Fields to Treat Fibrolamellar Carcinoma

A Barbara Ann Karmanos Cancer Institute and Wayne State University research team has received a $49,500 grant to research a rare cancer. The grant...

Read More

IN THE NEWS – New Hope for Myeloma Patients: Karmanos Advances Treatment and Survival

Telegram News Craig Cole, M.D. , malignant hematologist and member of the  Hematology Oncology  and  Multiple Myeloma and Amyloidos...

Read More
News

WDET | Doctor Says HPV Vaccine and Routine Screenings Aid Against Cervical Cancer

Listen Now

WWJ | World Cancer Day

Listen Now

WWJ | Ribbon Cutting Held for New Karmanos Cancer Center in Dearborn That Strives to Improve Access to Treatment, Clinical Trials

Listen Now